The VITALITY-HFpEF trial (Evaluate the Efficacy and Safety of the Oral sGC Stimulator Vericiguat to Improve Physical Functioning in Daily Living Activities of Patients With Heart Failure and Preserved Ejection Fraction) is designed to determine the efficacy and safety of a novel oral soluble guanylate cyclase stimulator, vericiguat, on quality of life and exercise tolerance in heart failure patients with preserved ejection fraction (HFpEF)
The VITALITY-HFpEF study was presented on June 12, 2020 during HFA Discoveries, an online initiative from the European Society of Cardiology Heart Failure Association.
Paul W. Armstrong; Carolyn S. P. Lam, Kevin J. Anstrom, Justin Ezekowitz, Adrian F. Hernandez, Christopher M. O’Connor, Burkert Pieske, Piotr Ponikowski, Sanjiv J. Shah, Scott D. Solomon, Adriaan A. Voors, Lilin She, Vanja Vlajnic, Francine Carvalho, Luke Bamber, Robert O. Blaustein, Lothar Roessig, Javed Butler; for the VITALITY-HFpEF Study Group. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. JAMA. 2020;324:1512-1521. doi:10.1001/jama.2020.15922.
Javed Butler, Carolyn S P Lam, Kevin J Anstrom, Justin Ezekowitz, Adrian F Hernandez, Christopher M O’Connor, Burkert Pieske, Piotr Ponikowski, Sanjiv J Shah, Scott D Solomon, Adriaan A Voors, Yi Wu, Francine Carvalho, Luke Bamber, Robert O Blaustein, Lothar Roessig, Paul W Armstrong. Rationale and Design of the VITALITY-HFpEF Trial. Circ Heart Fail. 2019 May;12:e005998. doi: 10.1161/CIRCHEARTFAILRE.119.005998.